IPOs

In $86M IPO pitch, Mirum spells out plans to turn Shire discards into orphan liver drug successes
In $86M IPO pitch, Mirum spells out plans to turn Shire discards into orphan liver drug successes
Endpoints
Mirum
IPOs
Shire
liver disease
Flag link:
Genetic Disease Focused Fulcrum Therapeutics Files for $86 Million IPO
Genetic Disease Focused Fulcrum Therapeutics Files for $86 Million IPO
CP Wire
Fulcrum Therapeutics
IPOs
FSHD
sickle cell disease
beta thalassemia
Flag link:
Genetic Disease Focused Fulcrum Therapeutics Files for $86 Million IPO
Fulcrum Therapeutics
IPOs
FSHD
sickle cell disease
beta thalassemia
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
Yahoo/Benzinga
Merck
Keytruda
Melinta Therapeutics
Amag Pharmaceuticals
Palatin
Acer Therapeutics
Sanofi
Regeneron
Alexion
Pfizer
Roche
Navidea Biopharmaceuticals
Ascendis Pharma
Scholar Rock
Adaptive Biotechnologies
BridgeBio
IPOs
G Medical Innovations
Karuna
Morphic Therapeutics
Flag link:
Four More Through the IPO Door as Life Science Firms Raise $465M
Four More Through the IPO Door as Life Science Firms Raise $465M
Xconomy
IPOs
Personalis
Akero Therapeutics
Prevail Therapeutics
Atreca
Flag link:
Stoke Therapeutics Upsizes IPO, Raises $142M for Dravet Drug R&D
Stoke Therapeutics Upsizes IPO, Raises $142M for Dravet Drug R&D
Xconomy
Stoke Therapeutics
IPOs
Dravet syndrome
Flag link:
Karuna Therapeutics Raises Its IPO Estimate to $85 Million
Karuna Therapeutics Raises Its IPO Estimate to $85 Million
CP Wire
Karuna Therapeutics
IPOs
schizophrenia
Alzheimer's disease
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs
The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs
Yahoo/Benzinga
FDA
Merck
Arqule
Affimed
BeiGene
Epizyme
MorphoSys
Theravance
Allena Pharma
Akero Therapeutics
Atreca
Dermavant Sciences
Personalis
Prevail Therapeutics
Stoke Therapeutics
IPOs
Flag link:
Change Healthcare Updates Filing for $1.2 Billion IPO and Equity Offering
Change Healthcare Updates Filing for $1.2 Billion IPO and Equity Offering
CP Wire
Change Healthcare
McKesson
IPOs
Flag link:
Ramaswamy's Dermavant Updates $124 Million IPO Filing
Ramaswamy's Dermavant Updates $124 Million IPO Filing
CP Wire
Dermavant
IPOs
tapinarof
psoriasis
dermatitis
Vivek Ramaswamy
Flag link:
Ramaswamy's Dermavant Updates $124 Million IPO Filing
Dermavant
tapinarof
psoriasis
dermatitis
IPOs
Flag link:
Personalis Updates $122 Million IPO Filing
Personalis Updates $122 Million IPO Filing
CP Wire
Perosnalis
IPOs
immuno-oncology
Flag link:
Personalis Updates $122 Million IPO Filing
Perosnalis
IPOs
Flag link:
Inhibrx Files for $75 Million IPO
Inhibrx Files for $75 Million IPO
CP Wire
Inhibrx
IPOs
Flag link:
Inhibrx Files for $75 Million IPO
Inhibrx
IPOs
Flag link:
Adaptive Biotechnologies Files for $230 Million IPO
Adaptive Biotechnologies Files for $230 Million IPO
CP Wire
Adaptive Biotechnologies
IPOs
Genentech
Flag link:
Adaptive Biotechnologies Files for $230 Million IPO
Adaptive Biotechnologies
Genentech
IPOs
Flag link:
Genmab files for $500M IPO to fund multi-front cancer R&D push
Genmab files for $500M IPO to fund multi-front cancer R&D push
Fierce Biotech
Genmab
IPOs
antibody-drug conjugate
cervical cancer
Flag link:
New IPO filings include BridgeBio, Dermavant, Prevail, Atreca, Akero
New IPO filings include BridgeBio, Dermavant, Prevail, Atreca, Akero
BioCentury
IPOs
BridgeBio
Dermavant
Prevail Therapeutics
Atreca
Akero Therapeutics
Flag link:
Ideaya wraps $50M IPO to fuel clinical drive on synthetic lethality
Ideaya wraps $50M IPO to fuel clinical drive on synthetic lethality
Endpoints
Ideaya
IPOs
cancer
Flag link:

Pages